Suyash Prasad

Summary

Publications

  1. ncbi request reprint A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD)
    Suyash Prasad
    Dept Neurosciences, Eli Lilly and Co Ltd, Basingstoke, UK
    Curr Med Res Opin 23:379-94. 2007
  2. ncbi request reprint The provision and nature of ADHD services for children/adolescents in the UK: results from a nationwide survey
    Michael Tettenborn
    Frimley Children s Centre, UK
    Clin Child Psychol Psychiatry 13:287-304. 2008
  3. pmc Baseline values from the electrocardiograms of children and adolescents with ADHD
    Suyash Prasad
    Department of Neuroscience, Eli Lilly and Company Ltd, Basingstoke, Hampshire, UK
    Child Adolesc Psychiatry Ment Health 1:11. 2007
  4. ncbi request reprint Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence
    Suyash Prasad
    Department of Paediatrics, Cromwell Hospital, London, UK
    Paediatr Drugs 10:39-47. 2008
  5. doi request reprint Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK
    S Prasad
    Department Paediatrics, Cromwell Hospital, London, UK
    Int J Clin Pract 63:1031-40. 2009
  6. ncbi request reprint Atomoxetine hydrochloride and executive function in children with attention-deficit/hyperactivity disorder
    Joanne Barton
    J Child Adolesc Psychopharmacol 15:147-9. 2005

Collaborators

  • Susan Ball
  • David Coghill
  • Michael Tettenborn
  • Joanne Barton
  • Anne McClure
  • Somnath Banerjee
  • Mohan Chandola
  • Geetha Kugan
  • Sarah Jenkins
  • Saroj Jamdar
  • Duncan Manders
  • Joanne Parker
  • Karina Hart
  • Kanagasabai Puvanendran
  • Christopher Steer
  • John Dearlove
  • Nigel Speight
  • Stephen Ralston
  • Valerie Harpin
  • Arthur Speight
  • Chris Steer
  • Chunnaiah Yemula
  • Jorge Arellano
  • Chelvi Kukendra
  • Lynne Poole
  • Ian Male
  • Avninder Spencer
  • Louise Timlin
  • Senerath Perera
  • Nikos Myttas
  • Baljinder Singh
  • Patricia Mooney

Detail Information

Publications6

  1. ncbi request reprint A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD)
    Suyash Prasad
    Dept Neurosciences, Eli Lilly and Co Ltd, Basingstoke, UK
    Curr Med Res Opin 23:379-94. 2007
    ..e., improvements in quality of life/functional outcomes) of atomoxetine compared with standard current therapy (SCT) in UK paediatric patients with ADHD and to explore clinician/parent/child perceptions of ADHD...
  2. ncbi request reprint The provision and nature of ADHD services for children/adolescents in the UK: results from a nationwide survey
    Michael Tettenborn
    Frimley Children s Centre, UK
    Clin Child Psychol Psychiatry 13:287-304. 2008
    ..Results of the survey provide an important insight into the ADHD-related services provided by ADORE centres, as well as highlighting the availability and limitations of such services...
  3. pmc Baseline values from the electrocardiograms of children and adolescents with ADHD
    Suyash Prasad
    Department of Neuroscience, Eli Lilly and Company Ltd, Basingstoke, Hampshire, UK
    Child Adolesc Psychiatry Ment Health 1:11. 2007
    ..The present meta-analysis provides baseline ECG values (i.e., off medication) from approximately 6000 children and adolescents with attention-deficit/hyperactivity disorder (ADHD)...
  4. ncbi request reprint Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence
    Suyash Prasad
    Department of Paediatrics, Cromwell Hospital, London, UK
    Paediatr Drugs 10:39-47. 2008
    ..We conclude that patients with ADHD can be switched from neurostimulants, specifically methylphenidate, to atomoxetine, and may benefit from symptom improvement...
  5. doi request reprint Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK
    S Prasad
    Department Paediatrics, Cromwell Hospital, London, UK
    Int J Clin Pract 63:1031-40. 2009
    ..For attention-deficit/hyperactivity disorder (ADHD), economic evaluations have largely focused on pharmacotherapy, and results indicate that such treatments are cost-effective compared with other interventions...
  6. ncbi request reprint Atomoxetine hydrochloride and executive function in children with attention-deficit/hyperactivity disorder
    Joanne Barton
    J Child Adolesc Psychopharmacol 15:147-9. 2005